Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Nu-Med Plus (NUMD) EPS (Weighted Average and Diluted) (2016 - 2021)

Nu-Med Plus' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.0 for Q3 2021.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.0 for Q3 2021, changed N/A from a year ago — trailing twelve months through Sep 2021 was -$0.02 (changed N/A YoY), and the annual figure for FY2018 was -$0.03, down 160.0%.
  • EPS (Weighted Average and Diluted) for Q3 2021 was -$0.0 at Nu-Med Plus, up from -$0.0 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.05 in Q4 2017 to a low of -$0.01 in Q3 2018.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.0 (2021), against an average of $0.01.
  • The sharpest move saw EPS (Weighted Average and Diluted) soared 371.41% in 2017, then plummeted 476.5% in 2018.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.05 in 2017, then plummeted by 118.42% to -$0.01 in 2018, then skyrocketed by 85.08% to -$0.0 in 2021.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.0, -$0.0, and -$0.01 for Q3 2021, Q2 2021, and Q4 2018 respectively.